A prospective cohort study demonstrated that LNG-IUS is an effective approach for the management of patients affected with dysmenorrhea, menometrorrhagia, and adenomyosis. Researchers undertook this trial to explore the efficacy of LNG-IUS as medical therapy in 28 patients having symptomatic adenomyosis (diagnosed through transvaginal ultrasonography). 

A control group consisting of 27 symptomatic patients (dysmenorrhea and menorrhagia) without a transvaginal ultrasonographic diagnosis of adenomyosis was managed in a similar way. In both  cohorts, the ultrasonographic aspects and clinical symptoms of dysmenorrhea and menometrorrhagia were examined.

During LNG-IUS insertion and six months after insertion, the recruited subjects were assessed for: the presence of myometrial cysts, menstrual blood loss, elevated uterine volume, heterogeneous myometrial texture, globulous uterine morphology, uterine symmetry, change in the junctional zone, hyperechogenic lines crossing the myometrium, dysmenorrhea, and adenomyomas.

Following six months, a considerable decline in the uterine volume was noted in both groups. In individuals suffering from adenomyosis, an improvement in the heterogeneity of myometrial texture, uterine symmetry, visibility of the junctional zone, adenomyomas, hyperechogenic lines, and presence of myometrial cysts was witnessed. A decrease in blood loss was observed in both the groups and specifically in adenomyotic patients. In all the patients, substantial improvement in pain was noted.

Thus, LNG-IUS can be considered an effective therapy for improving uterine morphology, and also managing symptoms of dysmenorrhea, menometrorrhagia, and adenomyosis.